Armata Pharmaceuticals
Open
$7.50
Prev. Close
$7.53
High
$7.53
Low
$7.40
Market Snapshot
$277.68M
-1.0
-0.51
$1.24M
61
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 61 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 61 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Recently from Cashu
Armata Pharmaceuticals secures $25M credit to advance AP-SA02 against antimicrobial resistance.
Armata Pharmaceuticals, Inc. (Ticker: ARMP) has secured a $25 million credit agreement with Innoviva to advance its therapeutic programs aimed at combating antibiotic resistance. This funding plays a…
Armata Pharmaceuticals Advances Phage Therapy for Chronic Respiratory Infections with P7-1 Research
Armata Pharmaceuticals, Inc. makes headlines with the recent publication of a research paper in 'Communications Biology' that details the structural analysis of phage P7-1. This phage is a key compone…
Armata Pharmaceuticals' AP-SA02: A Breakthrough in Treating Complicated Staph. aureus Bacteremia
Innovative Phage Therapy Shows Promise Against Complicated Staph. aureus Bacteremia Armata Pharmaceuticals, a clinical-stage biotechnology firm, is at the forefront of an innovative approach to treati…
Armata Pharmaceuticals Advances AP-SA02 Bacteriophage Therapy for Complicated Staph. aureus Bacteremia
Armata Pharmaceuticals Advances Bacteriophage Therapy for Staph. aureus Bacteremia Armata Pharmaceuticals, Inc., a clinical-stage biotechnology firm dedicated to bacteriophage therapeutics, is set to…